GSK outlines 2025 growth driven by specialty medicines and new product launches
Q4 2024 Management View CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit ...
pharmaphorum7d
GSK says new inhaler will help slash its carbon footprint
GSK has pledged to 100% use of renewable across the company by 2025, and an 80% reduction in carbon emissions by 2030 en route to net zero across all its supply chain – including purchased goods ...
Pharmaceutical Technology5y
Join TSS webinar: ‘Master your supply chain with end-to-end visibility!’
Learn how GlaxoSmithKline saves millions of dollars and thousands of tonnes of CO2 with a clean, simple, and efficient ...
The pharmaceutical program, Energize, partners with X-ELIO to advance its climate goals
X-ELIO, a global leader in renewable energy, has signed a multi-buyer Power Purchase Agreement (PPA) with an Energize program ...
pharmaphorum4d
GSK to move HQ to central London, as Canary Wharf plans filed
The site will house around 3,000 people – including GSK's global leadership team, and teams supporting R&D, the supply chain, commercial operations, corporate functions, and HIV joint venture ...